Skip to main content
SpringerLink
Log in

Optimising Outcomes in Acute Pancreatitis

  • Therapy in Practice
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Acute pancreatitis is a common cause for presentation to emergency departments. Common causes in Western societies include biliary pancreatitis and alcohol (the latter in the setting of chronic pancreatitis). Acute pancreatitis also follows endoscopic retrograde pancreatography in 5 to 10% of patients, a group that could potentially benefit from prophylactic treatment.

Although episodes of pancreatitis usually run a relatively benign course, up to 20% of patients have more severe disease, and this group has significant morbidity and mortality. Therefore, attempts have been made to identify, at or soon after presentation, those patients likely to have a poor outcome and to channel resources to this group.

The mainstay of treatment is aggressive support and monitoring of those patients likely to have a poor outcome. Pharmacotherapy for acute pancreatitis (both prophylactic and in the acute setting) has been generally disappointing. Efforts initially focused on protease inhibitors, of which gabexate shows some promise as a prophylactic agent. Agents that suppress pancreatic secretion have produced disappointing results in human studies.

Infection of pancreatic necrosis is associated with high mortality and requires surgical intervention. In view of the seriousness of infected necrosis, the use of prophylactic antibacterials such as carbapenems and quinolones has been advocated in the setting of pancreatic necrosis. Similarly, data are accumulating to support the use of prophylactic antifungal therapy.

Recently, it has become apparent that the intense inflammatory response associated with acute pancreatitis is responsible for much of the local and systemic damage. With this realisation, future efforts in pharmacotherapy are likely to focus on suppression or antagonism of pro-inflammatory cytokines and other inflammatory mediators. Similarly, animal studies have demonstrated the importance of oxidative stress in acute pancreatitis, although to date there is a paucity of information regarding the efficacy of antioxidants.

Although the clinical course for most patients with acute pancreatitis is mild, severe acute pancreatitis continues to be a clinical challenge, requiring a multi-disciplinary approach of physician, intensivist and surgeon.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Table I
Fig. 1
Table II

Similar content being viewed by others

References

  1. Banks PA. Medical management of acute pancreatitis and complications. In: Go VLW, Dimagno EP, Gardner JD, et al., editors. The pancreas: biology, pathobiology and disease. 2 ed. New York: Raven Press, 1993: 593–611

    Google Scholar 

  2. Bradley ELD. A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta (GA); 1992 Sep 11–13. Arch Surgery 1993; 128(5): 586–90

    Google Scholar 

  3. Sternby B, O’Brien JF, Zinsmeister AR, et al. What is the best biochemical test to diagnose acute pancreatitis? Aprospective clinical study. Mayo Clinic Proceedings 1996; 71(12): 1138–44

    Article  PubMed  CAS  Google Scholar 

  4. Mayer AD, McMahon MJ. Biochemical identification of patients with gallstones associated with acute pancreatitis on the day of admission to hospital. Ann Surgery 1985; 201(1): 68–75

    CAS  Google Scholar 

  5. Kemppainen EA, Hedstrom JI, Puolakkainen PA, et al. Rapid measurement of urinary trypsinogen-2 as a screening test for acute pancreatitis [see comments]. N Engl J Med 1997; 336(25): 1788–93

    Article  PubMed  CAS  Google Scholar 

  6. Tenner S, Fernandez-del Castillo C, Warshaw A, et al. Urinary trypsinogen activation peptide (TAP) predicts severity in patients with acute pancreatitis. Int J Pancreatol 1997; 21(2): 105–10

    PubMed  CAS  Google Scholar 

  7. Larvin M, McMahon MJ. APACHE-II score for assessment and monitoring of acute pancreatitis [see comments]. Lancet 1989; II(8656): 201–5

    Article  Google Scholar 

  8. Larvin M. Assessment of clinical severity and prognosis. In: Beger HG, Warshaw AL, Buchler MW, et al., editors. The pancreas. Oxford: Blackwell Science; 1998: 489–502

    Google Scholar 

  9. Dominguez-Munoz JE, Carballo F, Garcia MJ, et al. Clinical usefulness of polymorphonuclear elastase in predicting the severity of acute pancreatitis: results of a multicentre study. Br JSurg 1991; 78(10): 1230–4

    Article  CAS  Google Scholar 

  10. Uhl W, Vogel R, Z’graggen K, et al. Diagnosis of acute pancreatitis: markers of pancreatic necrosis. In: Beger HG, Warshaw AL, Buchler MW, et al., editors. The pancreas. Oxford: Black-well Science; 1998: 472–478

    Google Scholar 

  11. Balthazar EJ, Robinson DL, Megibow AJ, et al. Acute pancreatitis: value of CT in establishing prognosis. Radiology 1990; 174(2): 331–6

    PubMed  CAS  Google Scholar 

  12. Ranson JHC, Rifkind KM, Roses DF, et al. Prognostic signs and the role of operative management in acute pancreatitis. Surg Obstet Gynecol 1974; 143: 209–219

    Google Scholar 

  13. Corfield AP, Cooper MJ, Williamson RC, et al. Prediction of severity in acute pancreatitis: prospective comparison of three prognostic indices. Lancet 1985; II(8452): 403–7

    Article  Google Scholar 

  14. Beger HG, Bittner R, Block S, et al. Bacterial contamination of pancreatic necrosis. A prospective clinical study. Gastroenterology 1986; 91(2): 433–8

    CAS  Google Scholar 

  15. Baillargeon JD, Orav J, Ramagopal V, et al. Hemoconcentration as an early risk factor for necrotizing pancreatitis. Am J Gastroenterol 1998; 93(11): 2130–4

    Article  PubMed  CAS  Google Scholar 

  16. Sigurdssen GH. Necrotizing pancreatitis: intensive care measures. In: Beger HG, Warshaw AL, Buchler MW, et al., editors. The pancreas. Oxford: Blackwell Science; 1998: 508–520

    Google Scholar 

  17. Kim DK, Fukuda T, Thompson BT, et al. Bronchoalveolar lavage fluid phospholipase A2 activities are increased in human adult respiratory distress syndrome. Am J Physiol 1995; 269(1 Pt 1):L109–18

    PubMed  CAS  Google Scholar 

  18. Widdison AL, Karanjia ND. Pancreatic infection complicating acute pancreatitis. Br J Surg 1993; 80(2): 148–54

    Article  PubMed  CAS  Google Scholar 

  19. Uhl W, Schrag H-J, M. WA, Buchler MW. The role of infection in acute pancreatitis. Dig Surg 1995; 11: 214–219

    Article  Google Scholar 

  20. Banks PA, Gerzof SG, Langevin RE, et al. CT-guided aspiration of suspected pancreatic infection: bacteriology and clinical outcome. Int J Pancreatol 1995; 18(3): 265–70

    PubMed  CAS  Google Scholar 

  21. Fedorak IJ, Ko TC, Djuricin G, et al. Secondary pancreatic infections: are they distinct clinical entities? Surgery 1992; 112(4): 824–30; discussion 830–1

    PubMed  CAS  Google Scholar 

  22. Bradley ELD. A fifteen year experience with open drainage for infected pancreatic necrosis. Surg Gynecol Obstet 1993; 177(3): 215–22

    PubMed  Google Scholar 

  23. Benveniste GL, Morris RG. Penetration of cefotaxime into pancreatic juice [letter]. Lancet 1985; I(8428): 588–9

    Article  Google Scholar 

  24. Pederzoli P, Falconi M, Bassi C, et al. Ofloxacin penetration into bile and pancreatic juice. J Antimicrob Chemother 1989; 23(5): 805–7

    Article  PubMed  CAS  Google Scholar 

  25. Minelli EB, Benini A, Bassi C, et al. Antimicrobial activity of human pancreatic juice and its interaction with antibiotics. Antimicrob Agents Chemother 1996; 40(9): 2099–105

    PubMed  CAS  Google Scholar 

  26. Pederzoli P, Orcalli F, Falconi M, et al. Penetration of mezlocillin into pancreatic juice [letter]. J Antimicrob Chemother 1986; 17(3): 397

    Article  PubMed  CAS  Google Scholar 

  27. Buchler M, Malfertheiner P, Friess H, et al. Human pancreatic tissue concentration of bactericidal antibiotics. Gastroenterology 1992; 103(6): 1902–8

    PubMed  CAS  Google Scholar 

  28. Craig RM, Dordal E, Myles L. The use of ampicillin in acute pancreatitis [letter]. Ann Intern Med 1975; 83(6): 831–2

    PubMed  CAS  Google Scholar 

  29. Howes R, Zuidema GD, Cameron JL. Evaluation of prophylactic antibiotics in acute pancreatitis. J Surg Res 1975; 18(2): 197–200

    Article  PubMed  CAS  Google Scholar 

  30. Trudel JL, Wittnich C, Brown RA. Antibiotic bioavailability in acute experimental pancreatitis. J Am Coll Surg 1994; 178: 475–9

    PubMed  CAS  Google Scholar 

  31. Pederzoli P, Bassi C, Vesentini S, et al. A randomized multicenter clinical trial of antibiotic prophylaxis of septic complications in acute necrotizing pancreatitis with imipenem. Surg Gynecol Obstet 1993; 176(5): 480–3

    PubMed  CAS  Google Scholar 

  32. Sainio V, Kemppainen E, Puolakkainen P, et al. Early antibiotic treatment in acute necrotising pancreatitis [see comments]. Lancet 1995; 346(8976): 663–7

    Article  PubMed  CAS  Google Scholar 

  33. Golub R, Siddiqi F, Pohl D. Role of antibiotics in acute pancreatitis: a meta-analysis. J Gastrointest Surg 1998; 2: 496–503

    Article  PubMed  CAS  Google Scholar 

  34. Schwartz M, Isenmann R, Meyer H, et al. Antibotika bei nekrotisierender pankreatitis. Ergebnisse einer kontrollierten Studie. Deutsch Med Wochenschr 1997; 122: 356–361

    Article  Google Scholar 

  35. Delcenserie R, Yzet T, Ducroix JP. Prophylactic antibiotics in treatment of severe acute alcoholic pancreatitis. Pancreas 1996; 13: 198–201

    PubMed  CAS  Google Scholar 

  36. Gianotti L, Munda R, Gennari R, et al. Effect of different regimens of gut decontamination on bacterial translocation and mortality in experimental acute pancreatitis. Eur J Surg 1995; 161(2): 85–92

    PubMed  CAS  Google Scholar 

  37. Lange JF, van Gool J, Tytgat GN. The protective effect of a reduction in intestinal flora on mortality of acute haemorrhagic pancreatitis in the rat. Heptol Gastroenterol 1987; 34(1): 28–30

    CAS  Google Scholar 

  38. Buchler MW, Gloor B, Muller CA, et al. Acute necrotizing pancreatitis: treatment strategy according to status of infection. Ann Surg 2000; 232: 627–9

    Article  Google Scholar 

  39. Grewe M, Tsiotos GG, Luque de-Leon E, et al. Fungal infection in acute necrotizing pancreatitis. J Am Coll Surgs 1999; 188(4): 408–14

    Article  CAS  Google Scholar 

  40. Shrikhande S, Friess H, Issenegger C, et al. Fluconazole penetration into the pancreas. Antimicrob Agents Chemother 2000; 44(9): 2569–71

    Article  PubMed  CAS  Google Scholar 

  41. Mier J, Leon EL, Castillo A, et al. Early versus late necrosectomy in severe necrotizing pancreatitis [see comments]. Am J Surg 1997; 173(2): 71–5

    Article  PubMed  CAS  Google Scholar 

  42. Baron TH, Thaggard WG, Morgan DE, et al. Endoscopic therapy for organized pancreatic necrosis. Gastroenterology 1996; 111(3): 755–64

    Article  PubMed  CAS  Google Scholar 

  43. Beger HG, Buchler M, Bittner R, et al. Necrosectomy and postoperative local lavage in necrotizing pancreatitis. Br J Surg 1988; 75(3): 207–12

    Article  PubMed  CAS  Google Scholar 

  44. Steinberg W, E., Schlesselman SE. Treatment of acute pancreatitis: comparison of animal and human studies. Gastroenterology 1987; 93: 1420–1427

    PubMed  CAS  Google Scholar 

  45. Andriulli A, Leandro G, Clemente R, et al. Meta-analysis of somatostatin, octreotide and gabexate mesilate in the therapy of acute pancreatitis. Aliment Pharmacol Ther 1998; 12(3): 237–45

    Article  PubMed  CAS  Google Scholar 

  46. Cavallini G, Tittobello A, Frulloni L, et al. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy — Italian Group [see comments]. N Engl J Med 1996; 335(13): 919–23

    CAS  Google Scholar 

  47. Saito I, Hashimoto S, Saluja A, et al. Intracellular transport of pancreatic zymogens during caerulein supramaximal stimulation. Am J Physiol 1987; 253 (4 Pt 1): G517–26

    PubMed  CAS  Google Scholar 

  48. Cameron JL, Mehigan D, Zuidema GD. Evaluation of atropine in acute pancreatitis. Surg Gynecol Obstet 1979; 148(2): 206–8

    PubMed  CAS  Google Scholar 

  49. Navarro S, Ros E, Aused R, et al. Comparison of fasting, nasogastric suction and cimetidine in the treatment of acute pancreatitis. Digestion 1984; 30(4): 224–30

    Article  PubMed  CAS  Google Scholar 

  50. Goebell H, Ammann R, Herfarth C, et al. A double-blind trial of synthetic salmon calcitonin in the treatment of acute pancreatitis. Scand J Gastroenterol 1979; 14(7): 881–9

    Article  PubMed  CAS  Google Scholar 

  51. Raptis SA, Ladas SD. Therapy of acute pancreatitis with somatostatin. Scand J Gastroenterol Suppl. 1994; 207: 34–8

    Article  PubMed  CAS  Google Scholar 

  52. Paran H, Neufeld D, Mayo A, et al. Preliminary report of a prospective randomized study of octreotide in the treatment of severe acute pancreatitis. J Am Coll Surgeon 1995; 181(2): 121–4

    CAS  Google Scholar 

  53. Arvanitidis D, Hatzipanayiotis J, Koutsounopoulos G, et al. The effect of octreotide on the prevention of acute pancreatitis and hyperamylasemia after diagnostic and therapeutic ERCP. Hepatol Gastroenterol 1998; 45(19): 248–52

    CAS  Google Scholar 

  54. Tulassay Z, Dobronte Z, Pronai L, et al. Octreotide in the prevention of pancreatic injury associated with endoscopic cholangiopancreatography. Aliment Pharmacol Ther 1998; 12(11): 1109–12

    Article  PubMed  CAS  Google Scholar 

  55. McKay CJ, Curran F, Sharpies C, et al. Prospective placebo-controlled randomized trial of lexipafant in predicted severe acute pancreatitis [see comments]. Br J Surg 1997; 84(9): 1239–43

    Article  PubMed  CAS  Google Scholar 

  56. Group BAPS. Early treatment with lexipafant, a platelet activating factor antagonistreduces mortality in acute pancreatitis: a double blind, randomized, placebo controlled study. Gastroenterology 1997; 113: A453

    Google Scholar 

  57. Press release. Oxford: British Biotech; 1999 Mar 25

  58. Hofbauer B, Saluja AK, Bhatia M, et al. Effect of recombinant platelet-activating factor acetylhydrolase on two models of experimental acute pancreatitis. Gastroenterology 1998; 115(5): 1238–47

    Article  PubMed  CAS  Google Scholar 

  59. Schoenberg MH, Birk D, Beger HG. Oxidative stress in acute and chronic pancreatitis. Am J Clin Nutr 1995; 62 (6 Suppl.): 1306S–1314S

    PubMed  CAS  Google Scholar 

  60. Whitely GSW, Scott PD, Schofield D, et al. Combined antioxidant and surgical approach to extensive haemorrhagic pancreatic necrosis. Gastroenterology 1993: A343

  61. Hayashi J, Kawarada Y, Isaji S, et al. Therapeutic effects of continuous intraarterial antibiotic infusion in preventing pancreatic infection in experimental acute necrotizing pancreatitis. Pancreas 1996; 13(2): 184–92

    Article  PubMed  CAS  Google Scholar 

  62. Takeda K, Sunamura M, Shibuya K, et al. Role of early continuous regional arterial infusion of protease inhibitor and antibiotic in nonsurgical treatment of acute necrotizing pancreatitis. Digestion 1999; 60 Suppl. 1: 9–13

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, E19, Mayo and Foundation Clinic, 200 1st Street, SW, Rochester, Minnesota, 55905, USA

    Ian D. Norton &  Jonathan E. Clain

Authors
  1. Ian D. Norton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan E. Clain
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jonathan E. Clain.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Norton, I.D., Clain, J.E. Optimising Outcomes in Acute Pancreatitis. Drugs 61, 1581–1591 (2001). https://doi.org/10.2165/00003495-200161110-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200161110-00005

Keywords

Search

Navigation